Personalis Announces a Partnership with Berry Genomics for China Expansion
11 6월 2020 - 5:05AM
Business Wire
Personalis, Inc. (Nasdaq:PSNL), a leader in advanced genomics
for cancer, today announced the partnership with Berry Genomics,
headquartered in the People’s Republic of China.
Personalis will be expanding business operations in the People’s
Republic of China in 2020, and plans to form a wholly-owned
subsidiary in Shanghai. The expansion will include building out a
laboratory operation for local customers to use its ImmunoID NeXT
PlatformTM, a commercial team to support local customers, and
general and administrative functions.
Under terms of the agreement, Berry Genomics will provide
Personalis certain services and local support.
“I’m pleased to be able to announce our partnership with the
highly regarded Berry Genomics, headquartered in the PRC,” said
John West, Chief Executive Officer. “Having achieved a high degree
of scale in our Menlo Park, CA operation, we are poised to expand
globally and entering into a partnership with a company that has
the track record and capabilities of Berry Genomics will help us
accelerate the ramp-up of our operation. Both companies have
benefited from experience founded in the origin of next generation
sequencing, and together we will take it even further.”
“We are excited to partner with Personalis, who is very well
known for transforming the development of next-generation cancer
therapies by providing more comprehensive molecular data,” said Dr.
Daixing Zhou, Chief Executive Officer of Berry Genomics. “We have
been focusing on disease detection and elucidating underlying
molecular mechanisms. This partnership will serve the
pharmaceutical community and ultimately enable them to develop
better therapeutics, a natural extension of our current
business.”
About Berry Genomics
Founded in May 2010, Berry Genomics is a leading company in
clinical genomics and life science in China. Berry Genomics is
dedicated to research, development and commercialization of genetic
test technologies in clinical applications. Berry Genomics aims to
assist accurate diagnosis of diseases throughout the full human
life circle, and to improve human health. As a company with strong
R&D capability, Berry Genomics pioneered the first NGS-based
genetic test, NIPT, in China back in 2010. The company currently
provides NGS-based tests for many genetic diseases and cancers from
preconception to adulthood. Berry Genomics has around 1500
employees dedicating to developing products and providing services
for over 4000 organizations and facilities home and abroad,
including hospitals, research institutions, universities and
corporations. Berry Genomics has been listed on A-share market in
China since 2017 under the stock code: 000710. For more
information, please visit https://www.berrygenomics.com.
About Personalis, Inc.
Personalis, Inc. is a growing cancer genomics company
transforming the development of next-generation therapies by
providing more comprehensive molecular data about each patient’s
cancer and immune response. The Personalis ImmunoID NeXT PlatformTM
is designed to adapt to the complex and evolving understanding of
cancer, providing its biopharmaceutical customers with information
on all of the approximately 20,000 human genes, together with the
immune system, from a single tissue sample. Personalis also
provides genomic information to the VA Million Veterans Program as
part of their goal to sequence over a million veteran genomes. The
Personalis Clinical Laboratory is GxP aligned as well as
CLIA’88-certified and CAP-accredited. For more information, please
visit www.personalis.com and follow Personalis on Twitter
(@PersonalisInc).
Forward Looking Statements
This press release contains or may imply "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements include all statements that are not
historical facts and can be identified by terms such as
“anticipate,” “believe,” “contemplate,” “continue,” “could,”
“estimate,” “expect,” “hope,” “intend,” “may,” “might,”
“objective,” “ongoing,” “plan,” “potential,” “predict,” “project,”
“should,” “target,” “will,” or “would” or similar expressions and
the negatives of those terms. For example, forward-looking
statements include statements regarding the timing and results of
Personalis’ expansion into the People’s Republic of China and
elsewhere internationally, the results of the partnership between
Personalis and Berry Genomics, and other future events. These
forward-looking statements are subject to risks and uncertainties,
including those related to the evolution of cancer therapies and
market adoption of our services, our ability to serve the Chinese
market, our expectations regarding future performance, and the
COVID-19 pandemic, as well as other risks and uncertainties
discussed in Personalis’ filings with the Securities and Exchange
Commission (SEC), including in the “Risk Factors” and “Management’s
Discussion and Analysis of Financial Condition and Results of
Operations” sections of the Company’s most recently filed periodic
reports on Forms 10-K and 10-Q and subsequent filings and in the
documents incorporated by reference therein, all of which may
significantly impact our business and operations, the business and
operations of our customers, our ability to access capital and the
value of our common stock. Except as otherwise required by law,
Personalis disclaims any intention or obligation to update or
revise any forward-looking statements, which speak only as of the
date hereof, whether as a result of new information, future events
or circumstances or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200610005814/en/
Investor Relations Contact: Caroline Corner
investors@personalis.com 415-202-5678
Media Contact: Jennifer Havlek pr@personalis.com
www.personalis.com 650-752-1300
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024